Listed Japanese companies ranked by income taxes paid in their latest fiscal year (cash flow statement, annual securities reports).
| # | Company | Taxes paid | Tax expense | Pre-tax income | Tax rate | Revenue |
|---|---|---|---|---|---|---|
| 1 | Chugai Pharmaceutical Co., Ltd. | ¥191B | ¥164B | ¥598B | 27.4% | ¥1.26T |
| 2 | Takeda Pharmaceutical Company Limited | ¥180B | ¥9.8B | −¥142B | — | ¥4.51T |
| 3 | Daiichi Sankyo Company, Limited | ¥128B | ¥12.7B | ¥292B | 4.3% | ¥2.12T |
| 4 | Astellas Pharma Inc. | ¥98.6B | ¥85.0B | ¥377B | 22.6% | ¥2.14T |
| 5 | Otsuka Holdings Co., Ltd. | ¥74.0B | ¥102B | ¥468B | 21.8% | ¥2.47T |
| 6 | Shionogi & Co.,Ltd. | ¥41.0B | ¥33.0B | ¥239B | 13.8% | ¥500B |
| 7 | Eisai Co., Ltd. | ¥16.7B | ¥10.5B | ¥51.0B | 20.5% | ¥825B |
| 8 | ONO Pharmaceutical Co., Ltd. | ¥16.4B | ¥22.7B | ¥92.7B | 24.5% | ¥516B |
| 9 | Tsumura & Co. | ¥12.6B | ¥10.8B | ¥41.0B | 26.3% | ¥193B |
| 10 | Rohto Pharmaceutical Co., Ltd. | ¥11.9B | ¥12.4B | ¥46.8B | 26.5% | ¥344B |
| 11 | Kaken Pharmaceutial Co., Ltd. | ¥10.7B | ¥168M | ¥2.3B | 7.3% | ¥76.9B |
| 12 | Nippon Shinyaku Co.,Ltd. | ¥10.2B | ¥6.7B | ¥36.5B | 18.5% | ¥171B |
| 13 | TOWA Pharmaceutical Co., Ltd. | ¥8.5B | ¥7.9B | ¥13.2B | 60.1% | ¥274B |
| 14 | PeptiDream Inc. | ¥8.1B | −¥1.6B | −¥5.3B | — | ¥18.5B |
| 15 | Santen Pharmaceutical Co., Ltd. | ¥7.4B | ¥9.9B | ¥47.4B | 20.8% | ¥292B |
| 16 | Sumitomo Pharma Co., Ltd. | ¥4.6B | −¥6.5B | ¥100B | -6.5% | ¥453B |
| 17 | Kissei Pharmaceutical Co., Ltd. | ¥3.4B | ¥2.9B | ¥16.9B | 17.3% | ¥97.4B |
| 18 | KYORIN Pharmaceutical Co., Ltd. | ¥2.9B | ¥1.0B | ¥4.5B | 22.5% | ¥126B |
| 19 | Zeria Pharmceutical Co., Ltd. | ¥2.7B | ¥2.8B | ¥11.2B | 24.8% | ¥89.2B |
| 20 | Mochida Pharmaceutical Co.,Ltd. | ¥2.4B | ¥3.3B | ¥11.2B | 29.2% | ¥117B |
| 21 | Fuji Pharma Co.,Ltd. | ¥2.2B | ¥1.0B | ¥4.0B | 25.0% | ¥51.7B |
| 22 | KOA Shoji Holdings Co., Ltd. | ¥1.9B | ¥1.8B | ¥5.5B | 32.2% | ¥24.7B |
| 23 | TAUNS Laboratories, Inc. | ¥1.8B | ¥2.4B | ¥7.9B | 30.4% | ¥14.4B |
| 24 | SAWAI GROUP HOLDINGS Co., Ltd. | ¥1.8B | ¥2.7B | ¥14.3B | 19.2% | ¥202B |
| 25 | Fuso Pharmaceutical Industries,Ltd. | ¥1.3B | ¥426M | ¥2.4B | 17.5% | ¥62.3B |
| 26 | Mizuho MEDY Co., Ltd. | ¥1.2B | ¥1.3B | ¥4.7B | 27.7% | ¥11.3B |
| 27 | GNI Group Ltd. | ¥763M | ¥2.5B | −¥4.6B | — | ¥26.8B |
| 28 | Eiken Chemical Co., Ltd. | ¥754M | ¥1.1B | ¥4.8B | 23.3% | ¥41.9B |
| 29 | Daito Pharmaceutical Co., Ltd. | ¥729M | ¥928M | ¥4.1B | 22.8% | ¥50.6B |
| 30 | Nxera Pharma Co., Ltd. | ¥241M | −¥2.4B | −¥14.9B | — | ¥29.6B |
| 31 | ASKA Pharmaceutical Holdings CO., Ltd. | ¥241M | ¥1.4B | ¥7.0B | 19.5% | ¥71.1B |
| 32 | Kohjin Bio Co., Ltd. | ¥228M | ¥81.2M | ¥332M | 24.5% | ¥4.9B |
| 33 | YUKI Gosei Kogyo Co., Ltd. | ¥226M | ¥48.0M | ¥361M | 13.3% | ¥15.4B |
| 34 | StemCell Institute Inc. | ¥184M | ¥86.8M | ¥218M | 39.8% | ¥2.8B |
| 35 | Muromachi Chemicals Inc. | ¥159M | ¥165M | ¥328M | 50.3% | ¥7.8B |
| 36 | Kidswell Bio Corporation | ¥152M | ¥11.1M | −¥403M | — | ¥6.6B |
| 37 | RaQualia Pharma Inc. | ¥142M | ¥165M | ¥438M | 37.6% | — |
| 38 | Ｈｅａｒｔｓｅｅｄ株式会社 | ¥107M | ¥98.4M | ¥289M | 34.0% | ¥3.0B |
| 39 | Nippon Chemiphar Co., Ltd. | ¥105M | ¥23.0M | ¥221M | 10.4% | ¥33.1B |
| 40 | Chukyoiyakuhin Co., Ltd. | ¥62.4M | ¥35.2M | ¥119M | 29.6% | ¥6.6B |
| 41 | Renascience Inc. | ¥45.2M | ¥1.0M | −¥300M | — | — |
| 42 | Taiko Pharmaceutical Co., Ltd. | ¥34.0M | ¥34.0M | ¥958M | 3.5% | ¥6.4B |
| 43 | Morishita Jintan Co., Ltd. | ¥33.0M | ¥144M | ¥773M | 18.6% | ¥12.7B |
| 44 | Wakamoto Pharmaceutical Co., Ltd. | ¥25.4M | ¥29.2M | ¥256M | 11.4% | ¥9.9B |
| 45 | AnGes, Inc. | ¥20.6M | −¥113M | −¥5.2B | — | — |
| 46 | Seikagaku Corporation | ¥17.0M | ¥36.0M | ¥1.5B | 2.4% | ¥36.6B |
| 47 | SymBio Pharmaceuticals Limited | ¥12.6M | ¥27.6M | −¥4.7B | — | ¥1.3B |
| 48 | StemRIM Inc. | ¥8.3M | ¥2.0M | −¥1.8B | — | — |
| 49 | Immuno-Biological Laboratories Co., Ltd. | ¥5.5M | −¥28.5M | ¥301M | -9.5% | ¥1.0B |
| 50 | J-Pharma Co.,Ltd. | ¥5.0M | ¥1.1M | −¥2.5B | — | — |
| 51 | Oncolys BioPharma Inc. | ¥4.0M | ¥4.0M | −¥2.1B | — | ¥28.5M |
| 52 | Healios K.K. | ¥4.0M | ¥103M | −¥2.1B | — | ¥104M |
| 53 | 株式会社Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏ | ¥3.7M | ¥3.7M | −¥422M | — | — |
| 54 | Chiome Bioscience Inc. | ¥3.6M | ¥3.2M | −¥980M | — | ¥593M |
| 55 | Perseus Proteomics Inc. | ¥3.2M | ¥1.9M | −¥716M | — | ¥136M |
| 56 | 株式会社メドレックス | ¥3.2M | ¥12.3M | −¥925M | — | ¥128M |
| 57 | 株式会社ファンペップ | ¥3.1M | −¥99.7M | −¥2.0B | — | — |
| 58 | ステラファーマ株式会社 | ¥2.9M | ¥2.9M | −¥778M | — | ¥323M |
| 59 | Cuorips Inc. | ¥2.9M | ¥3.8M | −¥1.0B | — | ¥212M |
| 60 | Nano Holdings, Inc. | ¥2.9M | ¥3.2M | −¥941M | — | ¥174M |
| 61 | Delta-Fly Pharma, Inc. | ¥2.6M | ¥2.5M | −¥1.6B | — | — |
| 62 | 株式会社サイフューズ | ¥2.5M | ¥2.5M | −¥761M | — | ¥231M |
| 63 | RIBOMIC Inc. | ¥2.4M | ¥1.2M | −¥1.1B | — | ¥3.0M |
| 64 | ノイルイミューン・バイオテック株式会社 | ¥2.4M | ¥2.4M | −¥791M | — | — |
| 65 | Chordia Therapeutics,Inc | ¥2.4M | ¥2.4M | −¥1.8B | — | — |
| 66 | OncoTherapy Science, Inc. | ¥2.2M | ¥2.2M | −¥908M | — | — |
| 67 | BrightPath Biotherapeutics Co., Ltd. | ¥1.9M | ¥2.4M | −¥1.3B | — | ¥84,000 |
| 68 | D.Western Therapeutics Institute, Inc. | ¥1.9M | ¥1.6M | −¥630M | — | ¥388M |
| 69 | K Pharma,Inc. | ¥1.6M | ¥2.7M | −¥990M | — | — |
| 70 | Kringle Pharma,Inc. | ¥1.5M | ¥1.5M | −¥915M | — | ¥72.2M |
| 71 | 株式会社ＰＲＩＳＭ ＢｉｏＬａｂ | ¥1.3M | ¥2.4M | −¥831M | — | ¥677M |
| 72 | CanBas Co.,Ltd. | ¥1.2M | ¥1.2M | −¥1.3B | — | — |
| 73 | イノバセル株式会社 | ¥1.0M | ¥1.3M | −¥2.9B | — | — |
| 74 | SanBio Company Limited | ¥955,000 | −¥449M | −¥4.3B | — | — |
| 75 | Modalis Therapeutics Corporation | ¥950,000 | ¥1.5M | −¥2.2B | — | — |
| 76 | TMS Co., Ltd | ¥950,000 | ¥791,000 | −¥715M | — | — |
| 77 | Kyowa Kirin Co.,Ltd. | ¥0 | ¥20.2B | ¥87.2B | 23.1% | ¥497B |
| 78 | JCR Pharmaceuticals Co.,Ltd. | ¥0 | ¥1.0B | ¥3.2B | 31.5% | ¥40.3B |
| 79 | Carna Biosciences, Inc. | ¥0 | ¥1.9M | −¥2.2B | — | ¥579M |
| 80 | ソレイジア・ファーマ株式会社 | ¥0 | ¥0 | −¥876M | — | ¥429M |
From the latest annual securities reports filed with EDINET. Fiscal years differ by company.